YD Bio (NASDAQ: YDES) has announced that it has entered into a Memorandum of Understanding (MOU) to merge with closely held EG BioMed—a biotechnology company specializing in DNA methylation–based cancer diagnostics and AI-driven biomarker analytics.
According to YD Bio, the proposed merger represents a strategic step in building an integrated, data-driven oncology platform spanning early cancer detection, real-world clinical data generation, and AI-enabled drug discovery.
In a statement, Ethan Shen, PhD, chairman and CEO of YD Bio, commented, “Prior to this announcement, EG BioMed’s cancer detection platform was approved for clinical adoption at three affiliated medical centers of Taipei Medical University. It is now being integrated into hospital workflows to assist clinicians in monitoring treatment response, disease progression, and recurrence.”
The company notes that early use at these centers may demonstrate clinical and economic value, which could support wider adoption across additional institutions. Broader uptake, if achieved, may contribute to diagnostics revenue growth and inform future therapeutic development.
